ALMS Alumis Inc. Common Stock
USHealthcareAs of 2026-07-09 16:00
Why ALMS matters now
Alumis Inc. Common Stock (ALMS) is a US stock in Healthcare. The latest InvestLog snapshot shows $30.30 with +1.88% on the session and $3.74B in market capitalization; recent performance reads 1-month +8.73% and YTD +139.86%.
The latest financial table shown here is Q1 2026, with revenue of $1.7M, net income of $-93.1M, and EPS of $-0.74. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -13.0%.
The latest indexable market news headline is "Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $39.00; recent insider activity includes Drappa Jorn filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.16
P/S
343.91
EV/EBITDA
-6.91
DCF Value
$1.09
FCF Yield
-13.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.6%
Operating Margin
-5364.0%
Net Margin
-2825.7%
ROE
-54.6%
ROA
-35.4%
ROIC
-71.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.7M | $-93.1M | $-0.74 |
| Q4 2025 | $1.9M | $-92.9M | $-0.89 |
| FY 2025 | $24.1M | $-243.3M | $-2.32 |
| Q3 2025 | $2.1M | $-110.8M | $-1.06 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$39.33
Target (Median)
$39.00
Target Range
$25.00 - $51.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.54
Alumis Inc. is a biopharmaceutical firm currently in the clinical trial phase, dedicated to advancing and marketing therapeutic solutions for a range of autoimmune conditions. Its pipeline includes ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor, which is being investigated for its potential in addressing plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Another key candidate is A-005, also an allosteric TYK2 inhibitor, specifically designed to penetrate the central nervous system to target neuroinflammatory and neurodegenerative disorders. Originally established as Esker Therapeutics, Inc., the organization rebranded as Alumis Inc. in January 2022. Founded in 2021, Alumis maintains its corporate headquarters in South San Francisco, California.